Field: Technology

Study of 750,000 pregnancies reveals a surprising twist about Ozempic and Wegovy

Published | Technical Staff

Study of 750,000 pregnancies reveals a surprising twist about Ozempic and Wegovy

Visualization

In a landmark investigation involving over 750,000 pregnancies, a substantial dataset has catalyzed a re-evaluation of the potential risks associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), specifically Ozempic and Wegovy, during early gestation. Researchers uncovered a nuanced distinction in pregnancy-related outcomes based on the therapeutic context of these medications—whether prescribed for weight management or for diabetes.

Among the cohort studied, which comprised 756,636 pregnancies conducted between October 1, 2009, and December 31, 2023, a cohort analysis was performed. Researchers utilized Denmark's nationwide health registries to meticulously vet prescription records and correlate them with pregnancy outcomes. They defined accidental exposure to GLP-1 medications as a prescription filled during the critical eight weeks before and after the last menstrual period, a timeframe encompassing both undiagnosed pregnancy and the initial stages of organogenesis.

The exploration into the pregnancies revealed a paradoxical finding: while early exposure to these weight loss drugs showed no significant linkage to increased pregnancy complications among women using them for weight loss, a marked elevation in the risk of premature birth was discerned in patients who were prescribed GLP-1 RAs for managing diabetes. The odds ratios adjusted for co-founding variables, including maternal age, body mass index (BMI), smoking habits, educational attainment, prior health conditions such as diabetes, as well as time-related confounding due to seasonal and temporal patterns, illuminated this complexity.

Specifically, diabetic women on liraglutide exhibited a 70% heightened risk of delivering prematurely, while those using semaglutide indicated an even more pronounced 84% increase. Interestingly, the adjusted odds ratio for premature birth in women with pre-existing diabetes using semaglutide was pegged at an 11% increase, with a near 9% increase for those taking liraglutide. These figures underscore the notion that the pharmacological effects of GLP-1 RAs may be secondary to the pathophysiological underpinnings of diabetes itself rather than a direct consequence of the drug exposure.

Professor Henriette Svarre Nielsen, spearheading the research from the Department of Gynecology and Obstetrics at Copenhagen University Hospital Hvidovre, articulated the urgency for a refined understanding of GLP-1 drug implications during pregnancy. The surging global prescriptions of GLP-1 RAs necessitate clarity in the existing medical guidelines that call for cessation of these medications prior to conception—advice that, until now, has been predicated on initial studies using model organisms rather than expansive human data.

The divergence in risks between therapeutic uses calls for a reevaluation of clinical counseling practices for women inadvertently exposed to these medications during critical early stages of pregnancy. Potential gestational risks such as pre-eclampsia, gestational diabetes, macrosomia, stillbirth, and placental complications were scrutinized but remained statistically negligible among those using GLP-1 RAs predominantly for weight management.

Dr. Kathrine Hviid, the lead author of the study, emphasized that it is imperative future research efforts begin to demarcate between women utilizing GLP-1 medications for the management of diabetes versus those engaging with these therapies for weight loss. The genesis of differing health profiles among these groups may have considerable implications for pregnancy outcomes, obscuring any potential safety data that could meaningfully guide perinatal care.

As the medical community grapples with the fallout of this expansive study, caution is advocated in modifying existing recommendations pertaining to GLP-1 RA use during pregnancy. While this research provides groundbreaking insight into the complex interplay of diabetes and pregnancy risks, the findings themselves do not warrant a general dispensation for the continuation of GLP-1 RAs in pregnant patients. The safety profile of these medications during early pregnancy is still shrouded in uncertainty, necessitating a continuum of research to fully delineate the matrices of risk associated with their usage across varying patient demographics.

In sum, this comprehensive analysis not only enriches our understanding of GLP-1 receptor agonist exposure in pregnancy but also portends critical shifts in clinical practices and research trajectories that could ultimately enhance maternal and neonatal health outcomes.